BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 36311764)

  • 41. Identification of 17 mRNAs and a miRNA as an integrated prognostic signature for lung squamous cell carcinoma.
    Zhang J; Bing Z; Yan P; Tian J; Shi X; Wang Y; Yang K
    J Gene Med; 2019 Aug; 21(8):e3105. PubMed ID: 31215090
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development and validation of a novel ferroptosis-related gene signature for predicting prognosis and immune microenvironment in head and neck squamous cell carcinoma.
    He F; Chen Z; Deng W; Zhan T; Huang X; Zheng Y; Yang H
    Int Immunopharmacol; 2021 Sep; 98():107789. PubMed ID: 34130150
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Single-Cell RNA Sequencing Reveals the Role of Epithelial Cell Marker Genes in Predicting the Prognosis of Colorectal Cancer Patients.
    Shen KY; Chen BY; Gao WC
    Dis Markers; 2022; 2022():8347125. PubMed ID: 35968507
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A prognostic signature based on immune-related genes for cervical squamous cell carcinoma and endocervical adenocarcinoma.
    Liu J; Wu Z; Wang Y; Nie S; Sun R; Yang J; Cheng W
    Int Immunopharmacol; 2020 Nov; 88():106884. PubMed ID: 32795900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq.
    Zhang D; Lu W; Cui S; Mei H; Wu X; Zhuo Z
    J Ovarian Res; 2022 Nov; 15(1):123. PubMed ID: 36424614
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prediction of risk and clinical outcome of cuproptosis in lung squamous carcinoma.
    Zhang Y; Zhou J; Li H; Liu Y; Li J
    BMC Pulm Med; 2023 Jun; 23(1):205. PubMed ID: 37308925
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prediction of Tumor Microenvironment Characteristics and Treatment Response in Lung Squamous Cell Carcinoma by Pseudogene OR7E47P-related Immune Genes.
    Zhao YQ; Zhang HH; Wu J; Li L; Li J; Zhong H; Jin Y; Lei TY; Zhao XY; Xu B; Song QB; He J
    Curr Med Sci; 2023 Dec; 43(6):1133-1150. PubMed ID: 38015361
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification and Validation of a Novel Signature Based on NK Cell Marker Genes to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma by Integrated Analysis of Single-Cell and Bulk RNA-Sequencing.
    Song P; Li W; Guo L; Ying J; Gao S; He J
    Front Immunol; 2022; 13():850745. PubMed ID: 35757748
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival.
    Chen RL; Zhou JX; Cao Y; Sun LL; Su S; Deng XJ; Lin JT; Xiao ZW; Chen ZZ; Wang SY; Lin LZ
    Front Immunol; 2020; 11():1933. PubMed ID: 33072067
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of prognostic biomarkers for cervical cancer based on programmed cell death-related genes and assessment of their immune profile and response to drug therapy.
    Feng S; Wang Z; Zhang H; Hou B; Xu Y; Hao S; Lu Y
    J Gene Med; 2024 Jan; 26(1):e3643. PubMed ID: 38044747
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic Significance of Glycolysis-Related Genes in Lung Squamous Cell Carcinoma.
    Kadasah SF
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256214
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A nine-long non-coding RNA signature for prognosis prediction of patients with lung squamous cell carcinoma.
    Huang G; Huang Q; Xie Z; Zhou H; Cao J; Shi L; Yang M
    Cancer Biomark; 2019; 26(3):239-247. PubMed ID: 31524143
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR.
    Liang YY; Huang JC; Tang RX; Chen WJ; Chen P; Cen WL; Shi K; Gao L; Gao X; Liu AG; Peng XT; Chen G; Huang SN; Fang YY; Gu YY
    World J Surg Oncol; 2018 Feb; 16(1):22. PubMed ID: 29394946
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of the Role and Regulation Mechanism of hsa-miR-147b in Lung Squamous Cell Carcinoma Based on The Cancer Genome Atlas Database.
    Ke D; Guo Q; Fan TY; Xiao X
    Cancer Biother Radiopharm; 2021 Apr; 36(3):280-291. PubMed ID: 33112657
    [No Abstract]   [Full Text] [Related]  

  • 55. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.
    Ren Q; Zhang P; Zhang X; Feng Y; Li L; Lin H; Yu Y
    Front Immunol; 2023; 14():1199040. PubMed ID: 37313409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Based on scRNA-seq and bulk RNA-seq to establish tumor immune microenvironment-associated signature of skin melanoma and predict immunotherapy response.
    Li S; Zhao J; Wang G; Yao Q; Leng Z; Liu Q; Jiang J; Wang W
    Arch Dermatol Res; 2024 May; 316(6):262. PubMed ID: 38795156
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A prognostic 4-gene expression signature for squamous cell lung carcinoma.
    Li J; Wang J; Chen Y; Yang L; Chen S
    J Cell Physiol; 2017 Dec; 232(12):3702-3713. PubMed ID: 28160492
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development and validation of a novel immune-related prognostic model in lung squamous cell carcinoma.
    Liu Z; Wan Y; Qiu Y; Qi X; Yang M; Huang J; Zhang Q
    Int J Med Sci; 2020; 17(10):1393-1405. PubMed ID: 32624696
    [No Abstract]   [Full Text] [Related]  

  • 59. Comprehensive Analysis of Immune Cell Infiltration of m6a-Related lncRNA in Lung Squamous Cell Carcinoma and Construction of Relevant Prognostic Models.
    Zhang P; Li H; Cheng X; Wang W
    Biomed Res Int; 2022; 2022():9139823. PubMed ID: 35872842
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development and validation of a novel immune-related prognostic signature in lung squamous cell carcinoma patients.
    Liu X; Zhao D; Shan Y; Cui W; Xie Q; Jiang J; Peng W; Zhang C; Duan C
    Sci Rep; 2022 Dec; 12(1):20737. PubMed ID: 36456645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.